H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE